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Abstract
Metastatic melanoma of unknown primary (MUP) is an uncommon melanocytic lesion found in distant sites with no evident
skin involvement. This case report presents a 75-year-old woman who underwent local excision for a lump in the right
temporal area, which had been present for 6 months and had been suspected to be a lipoma. Histology confirmed that the
tissue excised from the temporalismusclewas composed of atypical, heavily pigmentedmelanocytes.Her historywas negative
formelanocytic lesions, and examination and extensive investigation including imaging had failed to identify a primary lesion.
The patient is currently being followed up.
INTRODUCTION
Malignantmelanoma is the commonest skin tumour worldwide,
although it is known to occur in other organs, and its incidence
is on the rise [1]. Metastatic melanoma of unknown primary
(MUP) is a melanocytic lesion in distant sites in the absence of
apparent skin involvement and is rare, accounting for up to 6% of
all incidentmelanomas [2] aswell as being yet poorly understood
in terms of pathogenesis.
CASE PRESENTATION
A 75-year-old woman presented to a surgical outpatients clinic
with a 6-month history of a lump in the right temporal area,
occasionally tender and slowly increasing in size. She denied
any hearing or visual symptoms and had no previous history
of malignant melanoma or the presence of any melanocytic
skin lesion. However, she reported an episode of trauma to the
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right temporal area ∼6 months previously. She is hypertensive,
asthmatic and an ex-smoker.
On examination, the patient had a 4-cm non-tender slightly
fluctuant non-pulsatile mass over the right temporal area,
clinically suggestive of a lipoma. On examination, there were
no melanocytic naevi on the overlying and surrounding skin,
and fundoscopy was normal. Blood investigations were within
normal limits, except for thyroid function tests, which were sug-
gestive of hypothyroidism. Computed tomography (CT) imaging
of the head, neck and thorax demonstrated a 2 × 4 x 4 cm
well-defined subcutaneous enhancing soft tissue formation
in the right temporal fossa (Fig. 1). There was no cervical
lymphadenopathy and no lung consolidation or suspicious lung
nodules.
At excision of the lesion under local anaesthesia, a collection
of dark semi-solidmaterialwithin the temporalismuscle, resem-
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Figure 1: This image shows the 2 x 4 x 4 cm right temporal fossa lesion as seen
on CT brain in the axial plane.
She underwent primary closure of the wound, with intraopera-
tive insertion of a drain that was removed the following day prior
to discharge.
The patient was followed up at the surgical outpatients clinic
(Fig. 2). Histology confirmed that the tissue was composed of
atypical, heavily pigmented melanocytes and was negative for
BRAFV600 mutation (Fig. 3). She was referred for review by an
oncologist and a dermatologist. A positron emission tomogra-
phy–computed tomography (PET–CT) scan showed a sizeable
focus of abnormal increased uptake in the right temporalis
region with no other evidence of abnormal tracer accumulation.
She was later started on nivolumab for Stage 4 melanoma, but
within 4 months was noted to have developed local progression
of disease and new liver metastasis on a follow-up PET–CT scan.
She is currently being managed palliatively.
DISCUSSION
Malignant melanoma is an aggressive tumour of melanocytes,
which are derivatives of the neural crest cells [1], and its common
presentations as cutaneous, mucosal or ocular lesions allow for
its classification [3].MUP is defined as a histologically confirmed
melanoma found in skin, subcutaneous or visceral tissues or
lymphnodes,with nomanifestation of a primary lesion [3].MUPs
comprise up to 6% of diagnosed melanomas, 60% of which are
present in lymph nodes, and reports of intramuscular lesions as
in this case are rare [3]. To our knowledge, this is only the fourth
such report [3–5]; as in Mercer and Deveraj’s [4] case, a diagnosis
was reached upon excision and investigation failed to identify a
primary.
The pathogenesis for MUP is not well understood; however,
potential aetiology includes the spontaneous regression of a
previously unrecognized primary melanoma [6] after metastatic
spread [7] or a previous melanoma that was removed as a result
of trauma or excised with no [6] or an incorrect pathological
diagnosis [7]. The presence of concurrent clinical unrecognized
Figure 2: This image shows the post-operative scar in the right temporal region.
Figure 3: This image shows a tumour comprised of neoplastic epithelioid cells
with prominent central nucleoli, most of which feature cytoplasmic melanin.
melanoma or de novo malignant transformation of an ectopic
melanocyte at a visceral site or lymph node have also been
proposed as causing MUP [2]. Lee et al. [6] propose that MUP
is most likely a result of immune-induced regression of the
primary tumour. This is because increased CD3 T-lymphocytes
and elevated expression of the interleukin 2 receptor (which
marks activated T-cells) have been identified in regressing pri-
mary melanomas in response to the presence of melanoma-
associated antigens [8]. Humoral mechanisms for regression
have also been suggested after identification of antibodies on
melanocyte cell membranes by immunofluorescence [6] and
following correlation of the endogenous immune response with
improved survival. It is likely that regression might involve a
combination of both humoral and cellular immune responses [6].
The predominantmutation linkedwithmelanoma (80–90%of
cutaneous primarymelanoma) is the BRAFmutation type V600E,
which has been associatedwith shorter survival [9], and a similar
mutation profile between cutaneous primary melanoma and
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mutation status does not appear to have a significant impact on
prognosis [7].
The 5-year overall survival rates of patients with MUP are
reported to range between 28.6 and 75.6% in patients who
present with lymph node disease and from 5.9 to 18% in patients
who present with visceral disease [10]. Furthermore, patients
withMUP and lymphnode disease have similar or better survival
in comparison with stage-matched patients with melanoma
of known primary. Treatment depends upon the staging of
the lesion and can range from surgical excision to oncological
treatment with radiotherapy and chemotherapy [3] but should
be the same as that for stage-matched patients with melanoma
of known primary.
CONCLUSION
This case report illustrates the necessity of more research into
the pathogenesis andmanagement ofMUP, an unusual lesion for
which diagnosis is crucial to the clinical care of a patient. With
involvement of a multidisciplinary team for prompt diagnosis,
complete staging, adequate treatment and close follow-up, the
prognosis of patients with MUP can be improved.
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